Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

Delayed Quote. Delayed  - 02/11 09:50:37 am
100.01 USD   -1.69%
02/09DJPanel Recommends FDA Approval of Remicade Knockoff
02/09DJPanel Recommends FDA Approval of Remicade Knockoff
02/09 JOHNSON & JOHNS : FDA panel backs lower-cost version of J&J's top-se..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Johnson & Johnson : FDA : J&J Unit Recalls Potentially Flammable Bone Putty

08/21/2012 | 06:13pm US/Eastern
   By Ben Fox Rubin 
 

The Food and Drug Administration said Johnson & Johnson (JNJ) unit Synthes last month initiated a recall on certain lots of bone putty, saying the medical product could catch fire during surgery.

The FDA gave the recall a Class I designation, its most serious type of recall.

The regulator said Synthes in early July issued a medical device recall letter, asking medical facilities to examine their inventories and immediately stop using specific lots of the putty. The product, called a hemostatic bone putty, is used to stop bone bleeding by creating a physical barrier along the edges of bones that have been damaged by trauma or cut during surgery.

The FDA said the putty could ignite under some conditions if contacted with certain surgical equipment.

The lots recalled were manufactured between July 6, 2011, and Dec. 14, 2011, and were distributed from Dec. 22, 2011, to June 25, 2012.

J&J in June completed its $19.7 billion purchase of medical-device maker Synthes. The health-care giant has worked to tackle a range of problem products, such as the bottles of children's Tylenol and other popular over-the-counter medicines, as well as some contact lenses and certain hip implants, that the company recalled due to manufacturing problems.

The company's shares closed Tuesday at $67.78 and were up 15 cents after hours. The stock is up 3.4% so far this year.

Write to Ben Fox Rubin at ben.rubin@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

React to this article
Latest news on JOHNSON & JOHNSON
08:59a JOHNSON & JOHNSON : Universal McCann named 'media agency of 2016'
08:56a JOHNSON & JOHNSON : Adweek names Universal McCann as Media agency of the year 20..
02/10 JOHNSON & JOHNSON : Announcement that Universal McCann
02/09DJPanel Recommends FDA Approval of Remicade Knockoff
02/09DJPanel Recommends FDA Approval of Remicade Knockoff
02/09 JOHNSON & JOHNSON : FDA panel backs lower-cost version of J&J's top-selling drug
02/09 Johnson & Johnson hires FedEx's GENCO to run Memphis center
02/09 JOHNSON & JOHNSON : to Participate in RBC Capital Markets Global Healthcare Conf..
02/08 JOHNSON & JOHNSON : RHINOCORT® Allergy Spray Now Available Over The Counter Nati..
02/08 GOLDMAN SACHS : Dow Movers: GS, JNJ
Advertisement
News chart
Full-screen chart
Income Statement Evolution
More Financials